SGSourav Ghosh

Sourav Ghosh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sourav Ghosh has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted modulation of NF-κB1 in neurodegenerative diseases

    by Priyanka Banerjee, Rakesh Das, Amartya Sen, Monosiz Rahaman, Saptarshi Sanyal, Sourav Ghosh

  • Deciphering the anxiolytic mechanism of glycowithenolides from Withania somnifera: insights from network pharmacology, molecular docking, and simulation studies

    by Monosiz Rahaman, Sourav Ghosh

    Anxiety is one of the most common mental health disorders today, often leading to panic, restlessness, and tension. Conventional treatments can cause adverse effects, prompting interest in plant-based alternatives. Glycowithanolides from Withania somnifera (WSGs) have demonstrated neuroprotective effects, but their role in anxiety management remains underexplored. This study evaluates the anxiolytic potential of WSGs using an integrated computational approach combining pharmacokinetic profiling, network pharmacology, molecular docking, and molecular dynamics (MD) simulations. Eleven WSGs exhibited favorable blood–brain barrier permeability and drug-likeness, complying with Lipinski’s Rule of Five. Network pharmacology revealed key interactions between WSGs and anxiolytic pathways such as cAMP, Ras, and calcium signaling, as well as addiction-related pathways. Genes like GRIN1, CHRM1, NFKB1, and HDAC2 emerged as potential targets, with GRIN1 identified as the central hub. Molecular docking of the WSGs with GRIN1 (PDB ID: 5EWM) indicated strong binding affinities, and the best-scoring ligand–receptor complex was further evaluated through MD simulations to assess stability and interactions. Results suggest strong binding of WSGs to GRIN1 and indicate a potential modulatory role; however, the proposed mechanism remains hypothesis-generating and requires experimental validation. Overall, this study highlights the therapeutic promise of glycowithanolides in managing anxiety disorders and offers a mechanistic basis for future experimental validation. The alternative text for this image may have been generated using AI.

  • Emblica officinalis Fraction Mitigates Depression via PI3K‐AKT Pathway: A Pharmacological Study

    by Amartya Sen, Sourav Ghosh, Monosiz Rahaman, Sheikh Murtuja, Bhupendra Prajapati, Biswajit Basu

    This study investigates the antidepressant potential of a pyrogallol‐enriched fraction of Emblica officinalis Gaertn. fruit (PEFEO) in a chronic unpredictable mild stress (CUMS) model of depression in mice, supported by in silico and in vivo evaluations. In vivo studies were conducted with PEFEO (100 and 200 mg/kg, p.o.) and fluoxetine (20 mg/kg, p.o.) as a standard. Behavioural assessments, including forced swim, Y‐maze, open field, and sucrose preference tests, demonstrated the antidepressant effects of PEFEO. Serum pro‐inflammatory cytokines (IL‐1β, TNF‐α, IL‐6) were quantified using ELISA, revealing significant reductions following PEFEO treatment. In silico ADMET profiling indicated favourable pharmacokinetic properties of pyrogallol. Network pharmacology suggested involvement of the PI3K signalling pathway in mediating its antidepressant effect, further supported by molecular docking and dynamic simulations with key target genes (NFKB1, CHRM1, CCNE1). Collectively, the findings suggest that PEFEO mitigates depression by modulating behavioural responses and suppressing inflammatory mediators, potentially via PI3K–AKT pathway regulation. This integrative approach underscores pyrogallol as a promising phytoconstituent for the management of depression with associated anti‐inflammatory effects.

  • Engineered living materials: emerging frontiers in therapeutic innovation and management of skin disorders

    by Rideb Chakraborty, Naureen Afrose, Sourav Ghosh, Bhupendra Prajapati, Biswajit Basu, Sudarshan Singh

    Engineered living material (ELM) is a new paradigm in biomaterials science that merges synthetic biology with materials engineering to create dynamic, responsive systems with living functionalities. This review explores to what extent ELMs can be developed as novel therapeutic agents for dermal complications including chronic wounds, burns, infections, and dermatological disorders. By integrating engineered microorganisms, such as bacteria or fungi, within biocompatible matrices, ELMs offer unprecedented capabilities for real-time sensing, adaptive responses, and localized therapeutic delivery. These materials can be formulated to release bioactive compounds, including antimicrobial, growth, or immunomodulatory peptides, in response to well defined environmental cues that address the underlying complexity of the pathophysiology of skin related conditions. ELMs have self-healing features and can remodel their structure to induce tissue regeneration and repair dynamically. This review summarizes recent progress in ELM design, including genetic circuit engineering, scaffold optimization, and biocompatibility enhancements that collectively enable precise control over their therapeutic functions. The clinical translation challenges including biosafety, scalability, and regulatory issues have been outlined. ELMs bridge the gap between synthetic biology and dermatology, by which ELMs have potential to be used as the next generation therapy platforms, empowered with personalized, sustainable, and efficacious treatments for dermal complications.


  • Natural Product Interventions in Peripheral Diabetic Neuropathy: A Multi-target Approach

    by Monosiz Rahaman, Sourav Ghosh

    Peripheral diabetic neuropathy (PDN) is a well-known impediment of diabetes mellitus. That is one of the common kinds of neuropathy, categorized by reduced neuronal function in the minor limbs including excruciating neurological pain. A medical examination is used to subclassify asymmetric and symmetric neuropathy. Diabetes is associated with several pathways, one of which is the activation of the polyol route, the production of oxidative stress, poly ADP-ribose polymerase, the formation of advanced glycation outputs, and the pathways of hexosamine. Although there are a few symptomatic and supportive treatments in use, like antiarrhythmics, tricyclic medications, aldose reductase, opioid analgesics, protein kinase C inhibitors, and incretin the results are unimpressive. To bridge this space, herbal product-based treatment can be a very successful replacement. This narrative review tries to understand the research currently accessible on the function of different biological entities in the treatment of PDN. These chemicals are essential for lowering aldose reductase activity, oxidative-nitrosative stress, and neuronal death. They improve axonal regeneration, nerve transmission velocity, as well as antioxidant molecules while controlling glucose and HbA1c%. (Malondialdehyde, catalase, superoxide dismutase). They are renowned for their ability to reduce heat and mechanical hyperalgesia as well as tactile allodynia. Thus, these substances need to have their animal study and clinical efficiency assessed. Natural compounds may be auspicious participants in the fight against PDN that provide a glimpse of optimism to those in need.

  • Mechanistic Insights into the Neuroprotective Effects of Natural Products in Diabetic Neuropathy

    by Soumyadwip Ghosh, Dilwar Hossain Warshi, Sejuti Ray Chowdhury, Monosiz Rahaman, Sourav Ghosh

    Diabetic neuropathy (DN) is one of the prominent complications of diabetes, which can result in pain, impaired movement, and even amputation. There are different types of DN, which can cause pain in fatal situations. In addition to altering insulin signaling, hyperglycemia and dyslipidemia cause a number of pathological changes in vascular cells, glia, as well as in neurons that can cause nerve damage and, in the end, neuropathy. Diabetic neuropathy has a poor prognosis since it doesn't show symptoms for years after diabetes starts. Despite the abundance of medications on the market, pharmacological ineffectiveness and a wide spectrum of adverse effects restrict adherence. As a result, there is a growing need to find novel compounds that show promising effects in the management of severe pain disorders. The most promising sources of novel chemical entities with potential use in medicine continue to be plant-derived products. Those products influenced the various signaling pathways, including PI3K/AKT pathway, MAPK pathway, Oxidative stress, TNF-α signaling, cyclo-oxygenase (COX 2) pathway and other molecular pathways to act as novel therapeutics for diabetic neuropathy. Basically, this mechanistic approach is implemented to improve neuroprotective activity, especially phytoconstituents derived from bioactive compounds. As neurodegenerative diseases have a complicated pathogenesis, the medications that are available on the market only treat the symptoms. Therefore, it would be highly desirable to design pharmacophores for the management of DN, with bioactive substances that have strong neuroprotective effects, using a multi-target strategy.

  • Mechanistic insights into piperlongumine’s neuroprotective role against cisplatin-induced neuropathy: a network pharmacology, molecular dynamics, and experimental approach

    by Riya Jana, Sourav Ghosh, Monosiz Rahaman, Biswajit Basu, Bhupendra Prajapati

    This study aimed to evaluate the neuroprotective effect of piperlongumine (PL), a natural alkaloid, on cisplatin-induced peripheral neuropathy (CIPN) in a mouse model, and to elucidate the possible underlying mechanisms involved in its action. In our study, ADMET of PL was done using pkCSM-predicted pharmacokinetic and toxicity properties like molecular weight, saturation, polarity, and solubility. Network pharmacology determined the primary targets and pathways connected to PL's anti-neuropathic actions. Molecular docking and dynamics simulations were performed to explore PL's binding affinity and stability with inflammation targets. CIPN was induced in mice using the standard chemotherapeutic agent cisplatin. PL was administered post-induction, and behavioral assessments were conducted to evaluate neuropathic pain (hot plate, tail flick, and cold allodynia tests). Histological analysis of the sciatic nerve and inflammatory cytokine levels was measured using blood serum. The ADMET study via pkCSM shows that PL molecules have good solubility, low toxicity, and follow Lipinski’s rule, making them promising for CIPN. Network pharmacology revealed that PL modulates key targets involved in the neuroinflammation pathway, such as MAPK1, the IL-17 pathway, and neuronal damage. Docking and MD simulations confirmed strong and stable interactions between PL and target proteins. In animal experiments, PL significantly alleviated thermal hyperalgesia and cold allodynia, downregulated TNF-α, IL-1β, and MAPK1. Histopathological analysis showed preserved axonal integrity and reduced inflammatory infiltration. By integrating network pharmacology with molecular dynamics and experimental validation, this study is the first to elucidate the specific molecular mechanism of piperlongumine (PL) in a mouse model of cisplatin-induced neuropathy. We identified and then confirmed that PL's neuroprotective effects are driven by its direct interaction with key inflammatory targets, primarily MAPK1 and IL-1β, leading to the suppression of the neuroinflammatory cascade. Graphical Abstract